Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
GE HealthCare’s Economic Impact Across Utah
RefloDx Wins Trans Atlantic Angel Grand Prize.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements
AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS
Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025
Groundbreaking Preclinical Data Propel Clinical Milestone
Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development